About this trial
The purpose of this study is to estimate the effect of FSG (Kerecis) on hospital length of stay among adult patients with surgical wounds of at least 40cm2 requiring surgical debridement
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Has wound greater than or equal to 40cm2 requiring surgical debridement
Agreeable to follow up period of up to 1 year
Disqualifiers
Patients with wounds that do not require surgical debridement.
Patients with a known allergy or other sensitivity to fish material
Patients who are deemed unlikely to follow up (e.g., patients who live out of state).
Patients in police custody/incarcerated.
Trial design
Parallel
Treatments tested in this trial
Fish Skin Graft (FSG)
DeviceFSG will be applied to the wound bed, followed by a wound VAC at the time of surgical debridement
Wound Vacuum-Assisted Closure (VAC)
DeviceParticipants will have a wound VAC applied to their wound bed at the time of surgical debridement.
Treatment groups
Trial outcomes
Primary outcomes
Hospital length of stay
Secondary outcomes
Number of participants that have recurrent surgical site infection
Number of participants that require reoperation
Time to total wound healing
Number of participants that need skin graft
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: